Angiotensin II suppression in SARS-CoV-2 infection: a therapeutic approach.
作者信息
Lamas-Barreiro José María, Alonso-Suárez Mario, Fernández-Martín Jorge Julián, Saavedra-Alonso Jesus Angel
机构信息
Servicio de Nefrología, Complejo Hospitalario Universitario de Vigo, Vigo, España.
Servicio de Nefrología, Complejo Hospitalario Universitario de Vigo, Vigo, España.
出版信息
Nefrologia (Engl Ed). 2020 May-Jun;40(3):213-216. doi: 10.1016/j.nefro.2020.04.006. Epub 2020 Apr 30.
Abstract
摘要
相似文献
1
Angiotensin II suppression in SARS-CoV-2 infection: a therapeutic approach.新型冠状病毒感染中血管紧张素II的抑制作用：一种治疗方法。
Nefrologia (Engl Ed). 2020 May-Jun;40(3):213-216. doi: 10.1016/j.nefro.2020.04.006. Epub 2020 Apr 30.
2
The role of ACEIs/ARBs in COVID-19: Friend or foe?血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体阻滞剂在2019冠状病毒病中的作用：是友还是敌？
Med Hypotheses. 2020 Sep;142:109810. doi: 10.1016/j.mehy.2020.109810. Epub 2020 May 5.
3
Angiotensin converting enzyme-2 as therapeutic target in COVID-19.血管紧张素转换酶2作为COVID-19的治疗靶点
Diabetes Metab Syndr. 2020 Jul-Aug;14(4):637-639. doi: 10.1016/j.dsx.2020.05.022. Epub 2020 May 12.
4
Bioactive compounds with possible inhibitory activity of Angiotensin-Converting Enzyme-II; a gate to manage and prevent COVID-19.具有可能抑制血管紧张素转换酶-II活性的生物活性化合物；管理和预防COVID-19的一扇门。
Med Hypotheses. 2020 Oct;143:109841. doi: 10.1016/j.mehy.2020.109841. Epub 2020 May 16.
5
ACE2 and ACE: structure-based insights into mechanism, regulation and receptor recognition by SARS-CoV.ACE2 和 ACE：基于结构的 SARS-CoV 机制、调控和受体识别的见解。
Clin Sci (Lond). 2020 Nov 13;134(21):2851-2871. doi: 10.1042/CS20200899.
6
Can beta-adrenergic blockers be used in the treatment of COVID-19?β-肾上腺素能阻滞剂可用于治疗新型冠状病毒肺炎吗？
Med Hypotheses. 2020 Sep;142:109809. doi: 10.1016/j.mehy.2020.109809. Epub 2020 May 5.
7
Carvedilol and COVID-19: A Potential Role in Reducing Infectivity and Infection Severity of SARS-CoV-2.卡维地洛与2019冠状病毒病：在降低严重急性呼吸综合征冠状病毒2传染性和感染严重程度方面的潜在作用
Am J Med Sci. 2020 Sep;360(3):300. doi: 10.1016/j.amjms.2020.05.030. Epub 2020 May 28.
8
Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体阻滞剂对无高血压的新冠患者有益吗？
Pharmacol Res. 2020 Sep;159:104959. doi: 10.1016/j.phrs.2020.104959. Epub 2020 Jun 4.
9
COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?新型冠状病毒肺炎与血管紧张素转换酶抑制剂及血管紧张素受体阻滞剂：证据是什么？
JAMA. 2020 May 12;323(18):1769-1770. doi: 10.1001/jama.2020.4812.
10
Association of ACE2 receptor and ACEIs/ARBs with disease severity in COVID-19.血管紧张素转换酶2（ACE2）受体及血管紧张素转换酶抑制剂（ACEIs）/血管紧张素Ⅱ受体阻滞剂（ARBs）与新型冠状病毒肺炎（COVID-19）疾病严重程度的关联
Drug Discov Ther. 2020;14(4):161-170. doi: 10.5582/ddt.2020.03064.
引用本文的文献
1
Inflammation-Associated Cytotoxic Agents in Tumorigenesis.肿瘤发生过程中与炎症相关的细胞毒性因子
Cancers (Basel). 2023 Dec 22;16(1):81. doi: 10.3390/cancers16010081.
2
Design and study of bioisosteric analogues of the drug Molnupiravir as potential therapeutics against SARS-COV-2: an in silico approach.作为抗SARS-CoV-2潜在疗法的药物莫努匹韦生物电子等排类似物的设计与研究：一种计算机模拟方法
In Silico Pharmacol. 2023 Dec 2;12(1):1. doi: 10.1007/s40203-023-00171-3. eCollection 2024.
3
Host-Derived Cytotoxic Agents in Chronic Inflammation and Disease Progression.慢性炎症与疾病进展中的宿主源性细胞毒性因子
Int J Mol Sci. 2023 Feb 3;24(3):3016. doi: 10.3390/ijms24033016.
4
Air pollution and meteorological variables' effects on COVID-19 first and second waves in Spain.空气污染和气象变量对西班牙新冠疫情第一波和第二波的影响。
Int J Environ Sci Technol (Tehran). 2023;20(3):2869-2882. doi: 10.1007/s13762-022-04190-z. Epub 2022 May 4.
5
Mortality due to COVID-19 in Spain and its association with environmental factors and determinants of health.西班牙新冠病毒病（COVID-19）所致死亡率及其与环境因素和健康决定因素的关联
Environ Sci Eur. 2022;34(1):39. doi: 10.1186/s12302-022-00617-z. Epub 2022 Apr 26.
本文引用的文献
1
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust.血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂与英国多地点急性医院信托的严重 COVID-19 感染无关。
Eur J Heart Fail. 2020 Jun;22(6):967-974. doi: 10.1002/ejhf.1924. Epub 2020 Jul 7.
2
Drugs and the renin-angiotensin system in covid-19.新冠病毒肺炎中的药物与肾素-血管紧张素系统
BMJ. 2020 Apr 2;369:m1313. doi: 10.1136/bmj.m1313.
3
Reply to: 'Interaction between RAAS inhibitors and ACE2 in the context of COVID-19'.回复：“2019冠状病毒病背景下肾素-血管紧张素-醛固酮系统抑制剂与血管紧张素转换酶2的相互作用”
Nat Rev Cardiol. 2020 May;17(5):313-314. doi: 10.1038/s41569-020-0369-9.
4
Interaction between RAAS inhibitors and ACE2 in the context of COVID-19.在2019冠状病毒病背景下RAAS抑制剂与血管紧张素转换酶2之间的相互作用。
Nat Rev Cardiol. 2020 May;17(5):313. doi: 10.1038/s41569-020-0368-x.
5
Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies.新型冠状病毒（COVI-19 或 SARS-CoV-2）诱导促炎细胞因子（IL-1 和 IL-6）和肺部炎症：抗炎策略。
J Biol Regul Homeost Agents. 2020;34(2):327-331. doi: 10.23812/CONTI-E.
6
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
7
[Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia].[RAS 抑制剂可能是治疗 COVID-19 肺炎的良好选择]
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):219-222. doi: 10.3760/cma.j.issn.1001-0939.2020.03.016.
8
COVID-19 and the cardiovascular system.新型冠状病毒肺炎与心血管系统。
Nat Rev Cardiol. 2020 May;17(5):259-260. doi: 10.1038/s41569-020-0360-5.
9
Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2.全长人血管紧张素转化酶 2 识别 SARS-CoV-2 的结构基础。
Science. 2020 Mar 27;367(6485):1444-1448. doi: 10.1126/science.abb2762. Epub 2020 Mar 4.
10
Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics.血管紧张素受体阻滞剂可作为治疗 SARS-CoV-2 的候选药物。
Drug Dev Res. 2020 Aug;81(5):537-540. doi: 10.1002/ddr.21656. Epub 2020 Mar 4.
Zotero 插件